Longevity Habits in 2026: What the Evidence Actually Supports vs What's Hype

The longevity industry has produced a remarkable convergence of legitimate science, premature extrapolation, and outright marketing dressed as research. Peter Attia, Andrew Huberman, Bryan Johnson's Project Blueprint, and a dozen supplement companies are all citing scientific literature to support their recommendations, and some of those citations are more reliable than others. Here is my attempt to sort them by evidence quality.

The Evidence Hierarchy Worth Understanding

For longevity specifically, the gold standard evidence is difficult to obtain. Randomized controlled trials with longevity as an endpoint would require following people for decades, which is expensive and methodologically difficult. What we have instead: epidemiological studies (correlations between behaviors and longevity), mechanistic research (understanding why something might affect aging), animal studies (often extrapolated to humans with varying reliability), and surrogate endpoint studies (measuring markers associated with aging rather than longevity itself).

Each category is meaningful and each has limitations that the longevity industry regularly underplays. "This compound extends lifespan in mice by 30%" is real science and also does not mean it will extend human lifespan by 30%.

The Highest-Evidence Interventions

Not smoking: The evidence is overwhelming, the effect size is enormous, and the mechanism is well-understood. Smoking is the single most preventable cause of premature death with the strongest evidence base of any lifestyle factor. If this seems boring rather than interesting, that's partly because it's true rather than marketable.

Cardiovascular exercise: The epidemiological evidence for aerobic exercise reducing all-cause mortality is as strong as any lifestyle factor in medicine. The dose-response curve shows benefits from even small amounts (150 minutes per week of moderate activity) and increasing benefits up to about 300 minutes weekly, with diminishing returns above that. Zone 2 cardio specifically has a strong evidence base from cardiovascular medicine for heart and metabolic health.

Resistance training: Muscle mass preservation through aging is increasingly supported as a significant longevity factor. Sarcopenia (muscle loss with aging) is independently associated with mortality risk. The evidence for resistance training preventing sarcopenia and improving functional capacity through aging is solid. Two to three sessions weekly seems to provide the majority of the benefit.

Metabolic health: Blood glucose regulation, insulin sensitivity, and avoiding metabolic syndrome are strongly associated with longevity in epidemiological studies. The mechanisms are well-understood. The interventions are largely dietary and exercise-based rather than supplemental.

Sleep quality and duration: The research on sleep and all-cause mortality is consistent — both short sleep (under 6 hours) and very long sleep (over 9 hours) are associated with increased mortality. The mechanism is complex and still being elucidated; the epidemiological finding is consistent.

Moderate Evidence Interventions

Caloric restriction / time-restricted eating: Animal evidence for caloric restriction extending lifespan is strong and consistent. Human evidence is much less developed — the CALERIE trial showed metabolic benefits from 25% caloric restriction without clear mortality data, which would require decades of follow-up. Intermittent fasting and time-restricted eating have mechanistic support and short-term metabolic benefits; whether they extend human lifespan is not established.

Mediterranean diet pattern: Strong epidemiological association with cardiovascular health and reduced all-cause mortality. The PREDIMED trial provided randomized controlled evidence for cardiovascular benefits specifically. The evidence is better than for most dietary interventions and worth taking seriously, with the caveat that observational nutrition evidence has historically been less reliable than it appeared.

Lower Evidence / Premature Extrapolation

NMN/NR supplements: NAD+ precursors have strong mechanistic evidence in yeast and mouse models. Human trials exist but are primarily short-term studies measuring surrogate markers rather than clinical outcomes. The jump from "raises NAD+ in blood" to "extends human lifespan" is substantially larger than the current evidence supports. The supplements are not harmful; the marketing claims exceed the evidence.

Metformin for non-diabetics: An active area of research (TAME trial underway) with genuine scientific interest. Not yet ready for recommendation to healthy individuals based on current evidence. The mechanistic case is interesting; the outcome evidence in healthy non-diabetics doesn't exist yet.

Cold exposure, sauna, and many hormetic stressors: Mechanistic plausibility and some epidemiological association (Finnish sauna use and cardiovascular health). The longevity-specific claims significantly outrun the evidence.

Honest Bottom Line: The highest-evidence longevity interventions are not exciting: not smoking, regular cardio, resistance training, metabolic health maintenance, and adequate sleep. These have decades of epidemiological support and well-understood mechanisms. The interesting longevity research (NMN, caloric restriction protocols, senolytics) has genuine scientific merit and premature-extrapolation marketing. Most expensive longevity protocols are adding low-evidence interventions on top of high-evidence foundations, and the high-evidence foundations are doing most of the work.